A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

Congenital Myasthenic Syndrome Clinical Trial

Official title:

A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06436742
• Other study ID #: ARGX-119-2302
• Secondary ID: 2023-509872-41-0
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: June 2024
• Est. completion date: October 2025

Study information

• Verified date: May 2024
• Source: argenx
• Contact: Sabine Coppieters, MD
• Phone: 857-350-4834
• Email: clinicaltrials[@]argenx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of ARGX-119 in adult participants with DOK7- Congenital Myasthenic Syndromes. The study will also assess how ARGX-119 is processed by the body (pharmacokinetics), how the immune system reacts to it (immunogenicity), and how it may improve the way patients feel and function.

After the screening period, eligible participants will be randomized in a 4:1 ratio to receive intravenous infusions of ARGX-119 or placebo during the treatment period. Participants will then enter the follow-up period. The full duration of the study is approximately 11 months.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 15
• Est. completion date: October 2025
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years of age.

• Has genetically confirmed congenital myasthenic syndromes due to mutation of downstream of kinase 7 (DOK7-CMS).

• Participants taking oral beta agonists (eg, albuterol, salbutamol, ephedrine) must have been receiving the medication for more than 3 months and agree to remain on a same stable dosing regimen of the same medication until the end of the study.

Exclusion Criteria:

• Diagnosis of CMS due to mutation of any gene other than DOK7.

• Known medical condition that would interfere with an accurate assessment of CMS, confound the results of the study, or put the patient at undue risk, as assessed by the investigator.

• History of malignancy, cancer, unless considered cured by adequate treatment with no evidence of recurrence for more than 5 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer.

• Different study drug received in another clinical study within 12 weeks or 5 half-lives before screening.

• Current participation in another interventional clinical study or prior participation in any gene therapy or cell therapy study.

• Pregnant or lactating state or intention to become pregnant during the study.

The complete list of exclusion criteria can be found in the protocol.

Related Conditions & MeSH terms

• Congenital Myasthenic Syndrome
• Lambert-Eaton Myasthenic Syndrome
• Myasthenic Syndromes, Congenital
• Syndrome

Intervention

Biological:
• ARGX-119
Intravenous infusion of ARGX-119

Other:
• Placebo
Intravenous infusion of placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
argenx

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of adverse events (AEs)		Up to week 42
Secondary	Maximum observed serum concentration (Cmax) of ARGX-119		Up to week 42
Secondary	Incidence of anti-drug antibodies (ADA) against ARGX-119		Up to week 42
Secondary	Prevalence of anti-drug antibodies (ADA) against ARGX-119		Up to week 42
Secondary	Change from baseline over time for key components of the Quantitative Myasthenia Gravis (QMG) scale	Minimum value: 0 (no disease severity); Maximum value: 39 (highest disease severity)	Up to week 42
Secondary	Change from baseline over time for Myasthenia Gravis Activities of Daily Living (MG-ADL)	Minimum value: 0 (normal symptoms); Maximum value: 24 (most severe symptoms)	Up to week 42
Secondary	Change from baseline over time for Patient-Reported Outcomes Measurement Information System Global Health (PROMIS-GH) scale	The participant records their response to each question on a 5-point Likert scale, with lower scores indicating poorer health (Minimum value: 0, Maximum value: 20)	Up to week 42